 |
 |
Home |  |
 |
About us |  |
|
Principal investigators | |
|
Tools & Publications | |
|
Fellowships | |
|
Links | |
|
Contact us | |
|
February 2010 Meeting | |
|
Français |  |
 |
| Home |
|
|
APOGEE-Net/CanGèneTest is an international research and knowledge network studying health care and health policy challenges in genetic services, including genetic laboratory services. Its general objective is to streamline the technology transfer of clinically useful and cost/effective genetic innovations towards the health care system and support the development of evidence-informed health policies.Through a multidisciplinary approach, we aim to study the path that links the fundamental research discoveries in genetics to the use of molecular diagnostic tests in the clinical setting. Moreover, with our e-Newsletter and this WEB site, we expect to contribute to disseminate timely and relevant scientific materials to colleagues interested in this broad field of research, downstream of the gene discovery, necessary to translate the clinically valid and useful discoveries into novel health care services. CanGèneTest Newsletter Highlights : |
| 24 fév 2010 Testing curbs some genetic diseases Some of mankind's most devastating inherited diseases appear to be declining, and a few have nearly disappeared, because more people are using genetic testing to decide whether to have children. Births of babies with cystic fibrosis, Tay-Sachs and other less-familiar disorders have dropped since testing came into wider use, according to interviews with geneticists and other experts and a review of the limited research available. | |
| 24 fév 2010 A Collaborative Approach to Genetic Testing: A Community Hospital’s Experience (restricted access) The field of cancer genetics is evolving rapidly, and much has changed over the past ten years in the way services are being provided and by whom they are being provided. This study recounts here the experience with the evolution of cancer genetic services in a community setting, focusing on collaboration with non-genetics providers to offer genetic testing for hereditary cancer. This approach allows for the most effective use of genetic counselors’ expertise for challenging cases, and enables the patient to remain within their community to allow for better access to resources for long-term follow-up. | |
| 24 fév 2010 Revised Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests The scope of this study and report is on those genetic tests that rely on analysis of nucleic acid molecules to determine human genotype, whether used for diagnostic, predictive, or other clinical purposes. The Committee gathered information on both clinical access and patient access to such tests. | |
| 5 mars 2010 The CAPABILITY Report: Model Approaches for Capacity Building for the Translation of Genetic Knowledge into Practice and Prevention This report presents in detail the CAPABILITY approach for capacity building and the outcome of the CAPABALITY demonstration project. CAPABILITY is a 3-year model project funded by the European Commission. It is a specific support Action (SSA) for the Network of Excellence EuroGentest and aims at addressing the lack of internationally shared standards for genetic testing/services provisions and the lack of evidence-based models for assessing genetic services needs. | |
| 24 fév 2010 Genetic testing in cardiovascular diseases (restricted access) The aim of this study is to review the current state and different aspects, including the yield, of genetic counselling and genetic testing in inherited heart disease. The authors observed that with the increasing identification of associated genes and available techniques in molecular testing of the inherited heart diseases, the diagnostic yield of mutation analysis is growing rapidly. To determine the relevance of all these mutations, ongoing research is needed. Furthermore, the process of genetic counselling can be optimized and extended with cascade screening, which leads to identifying patients at risk and timely treatment. | |
|